Differential Expression of Cyclic Nucleotide Phosphodiesterase 3 and 4 Activities in Human T Cell Clones Specific for Myelin Basic Protein

Journal of Immunology

Volumn 159, Issue 3, 1997, Pages 1520-1529

  Ekholm, Dag ^a,c   Hemmer, Bernhard ^b   Gao, Guang ^a   Vergelli, Marco ^b   Martin, Roland ^b,d   Manganiello, Vincent ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^c LUND UNIVERSITY   (Sweden)

^d UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3',5' CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; EPITOPE; MESSENGER RNA; MYELIN BASIC PROTEIN; MYELIN BASIC PROTEIN 83 99; MYELIN BASIC PROTEIN 83-99; PEPTIDE FRAGMENT; PHOSPHODIESTERASE; PHOSPHODIESTERASE III; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV; THYMIDINE; TRITIUM;

ARTICLE; BIOSYNTHESIS; CELL CLONE; DRUG ANTAGONISM; DRUG EFFECT; ENZYME ACTIVATION; ENZYMOLOGY; HUMAN; IMMUNOLOGY; METABOLISM; POLYMERASE CHAIN REACTION; T LYMPHOCYTE SUBPOPULATION; TIME;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; CLONE CELLS; ENZYME ACTIVATION; HUMANS; IMMUNODOMINANT EPITOPES; MYELIN BASIC PROTEINS; PEPTIDE FRAGMENTS; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; POLYMERASE CHAIN REACTION; RNA, MESSENGER; T-LYMPHOCYTE SUBSETS; THYMIDINE; TIME FACTORS; TRITIUM;

EID: 0031204380     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Kammer. G. 1988. The adenylate cyclase-cAMP-protein kinase A pathway and the regulation of the immune response. Immunol. Today 8:222.
2. Beavo. J. 1995. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol. Rev. 75:725.
3. Nicholson, D., J. Challis, and M. Shahid. 1991. Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes. Trends Pharmacol. Sci. 12:19.
4. Manganiello, V. C., T. Murata, M. Taira, P. Belfrage, and E. Degerman. 1995. Diversity in cyclic nucleotide phosphodiesterase isoenzyme families. Arch. Biochem. Biophys. 322:1.
5. Dent, G., and M. Giembycz. 1996. Interaction of PDE4 inhibitors with enzymes and cell functions. In The Handbook of Immunopharmacology: Phosphodiesterase Inhibitors. C. Schudt, G. Dent, and K. Rabe, eds. Academic Press, San Diego, pp. 111.
6. Engels, P., K. Fichtel, and H. Lübbert. 1994. Expression and regulation of human and rat phosphodiesterase type IV isogenes. FEBS Lett. 350:291.
7. + T-lymphocytes: role in regulating proliferation and the biosynthesis of interleukin-2. Br. J. Pharmacol. 118:1945.
8. + lymphocytes. Clin. Exp. Allergy 25:616.
9. Tenor, H., A. Hatzelmann, R. Kupferschmidt, L. Stanciu, R. Djukanovic, C. Schudt, A. Wendel, M. Church, and J. Shute. 1995. Cyclic nucleotide phosphodiesterase isoenzyme activities in human alveolar macrophages. Clin. Exp. Allergy 25:625.
10. Stam, W., A. van Oosterhout, and F. Nijkamp. 1993. Pharmacologic modulation of TH1- and TH2-associated lymphokine production. Life Sci. 53:1921.
11. Schudt, C., H. Tenor, U. Loos, P. Mallman, M. Szamel, and K. Resch. 1993. Effects of selective PDE inhibitors on activation of human macrophages and lymphocytes. Eur. Respir. J. 6(Suppl. 17):367S.
12. Schade, U., and C. Schudt. 1993. The specific type III and IV phosphodiesterase inhibitor zardaverine suppresses formation of tumor necrosis factor by macrophages. Eur. J. Pharmacol. 230:9.
13. al-Essa, L., M. Niwa, K. Kohno, M. Nozaki, and K. Tsurumi. 1995. Heterogeneity of circulating and exudated polymorphonuclear leukocytes in superoxide-generating response to cyclic AMP and cyclic AMP-elevating agents. Biochem. Pharmacol. 49:315.
14. Robicsek, S., D. Blanchard, J. Djeu, J. Krzanowski, A. Szentevanyi, and J. Polson. 1991. Multiple high-affinity cAMP phosphodiesterases in human T-lymphocytes. Biochem. Pharmacol. 42:869.
15. Marcos, P., A. Prigent, M. Lagarde, and G. Nemoz. 1993. Modulation of rat thymocyte proliferalive response through the inhibition of different cyclic nucleotide phosphodiesterase isoforms by means of selective inhibitors and cGMP-elevating agents. Mol. Pharmacol. 44:1027.
16. Pan, X., E. Arauz, J. Krzanowski, D. Fitzpatrick, and J. Polson. 1994. Synergistic interactions between selective pharmacological inhibitors of phosphodiesterase isoenzyme families PDEIII and PDEIV to attenuate proliferation of rat vascular smooth muscle. Biochem. Pharmacol. 48:827.
17. Souness, J., G. Hassal, and D. Parrott. 1992. Inhibition of pig aortic smooth muscle cell DNA synthesis by selective type III and type IV cyclic AMP phosphodiesterase inhibitors. Biochem. Pharmacol. 44:857.
18. Matousovic, K., J. Grande, C. Chini, E. Chini, and T. Dousa. 1995. Inhibitors of cyclic nucleotide phosphodiesterase isozymes type-III and type-IV suppress mitogenesis of rat mesangial cells. J. Clin. Invest. 96:401.
19. Mosmann, T. R., H. Cherwinski, M. W. Bond, M. A. Giedlin, R. L. Coffman. 1986. Two types of murine helper T cell clones. I. Definition according to profiles of lymphokine activities and secreted proteins. J. Immmol. 136:2348.
20. Mosmann, T. R., and R. L. Coffman. 1989. Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7:145.
21. + T-cell subset with an unrestricted cytokine profile. J. Immunol. 143:518.
22. Kelso, A. 1995. Th1 and Th2 subsets: paradigms lost? Immunol. Today 16:374.
23. Hemmer, B., M. Vergelli, P. Calabresi, T. Huang, H. F. McFarland, and R. Martin. 1996. Cytokine phenotype of human autoreactive T cell clones specific for the immunodominant myelin basic protein peplide (83-99). J. Neurosci. Res. 45:1152.
24. Sommer, N., P. A. Loschmann, G. H. Northoff, M. Weller, A. Steinbrecher, J. P. Steinbach, R. Lichtenfels, R. Meyermann, A. Riethmuller, A. Fontana, J. Dichgans, and R. Martin. 1995. The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nat. Med. 1:244.
25. Jung, S., J. Zielasek, G. Kellner, T. Donhauser, K. Toyka, and H.-P. Hartung. 1996. Preventive but not therapeutic application of rolipram ameliorates experimental autoimmune encephalomyelitis in Lewis rats. J. Neuroimmunol. 68:1.
26. Genain, C. P., T. Roberts, R. L. Davis, M.-H. Nguyen, A. Ucchelli, D. Faulds, Y. Li, J. Hedgpeth, and S. L. Hauser. 1995. Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor. Proc. Natl. Acad. Sci. USA 92:3601.
27. Rott, O., E. Cash, and B. Fleischer. 1993. Phosphodiesterase inhibitor pentoxyfylline, a selective suppressor of T helper type 1- but not type 2-associated lymphokine production, prevents induction of experimental autoimmune encephalomyelitis in Lewis rats. Eur. J. Immunol. 23:1745.
28. Martin, R., H. F. McFarland, and D. F. McFarlin. 1992. Immunological aspects of demyelinating diseases. Annu. Rev. Immunol. 10:153.
29. Essayan, D. M., S.-K. Huang, B. Undem, A. Kagey-Sobotka, and L. M. Lichtenstein. 1997. Differential efficacy of lymphocyte- and monocyte-selective pretreatment with a type 4 phosphodiesterase inhibitor on antigen-driven proliferation and cytokine gene expression. J. Allergy Clin. Immunol. 99:28.
30. Deibler, G. E., R. E. Martenson, and M. W. Kies. 1972. Large scale preparation of myelin basic protein from central nervous system tissue of several mammalian species. Prep. Biochem. 2:139.
31. + cytotoxic T cell response specific for the immunodominant myelin basic protein peptide 87-106. J. Immunol. 148:1359.
32. Martin, R., M. D. Howell, D. Jaraquemada, M. Flerlage, J. Richert, S. Brostoff, E. O. Long, D. E. McFarlin, and H. F. McFarland. 1991. A myelin basic protein peptide is recognized by cytotoxic T cells in the context of four HLA-DR types associated with multiple sclerosis. J. Exp. Med. 173:19.
33. Manganiello, V. C., and M. Vaughan. 1973. An effect of insulin on cyclic adenosine 3-5-monophosphate phosphodiesterase activity in fat cells. J. Biol. Chem. 248:7164.
34. Meacci, E., M. Taira, M. Moos, C. Smith, M. Movsesian, E. Degerman, P. Belfrage, and V. Manganiello. 1992. Molecular cloning and expression of human myocardial cGMP-inhibited cAMP-phosphodiesterase. Proc. Natl. Acad. Sci. USA 89:3721.
35. Miki, T., M. Taira, S. Hockman, F. Shimada, J. Lieman, M. Napolitano, D. Ward, M. Taira, H. Makino, and V. Manganiello. 1996. Characterization of the cDNA and gene encoding human PDE3B, the cGIP1 isoform of the human cGMP-inhibited cyclic nucleotide phosphodiesterase family. Genomics 36:476.
36. Jiang, X., J. Li, M. Paskind, and P. Epstein. 1996. Inhibition of calmodulin-dependent phosphodiesterase induces apoptosis in human leukemic cells. Proc. Natl. Acad. Sci. USA 93:11236.
37. Epstein, D., and R. Hachisu. 1984. Cyclic nucleotide phosphodiesterase in normal and leukemic human lymphocytes and lymphoblasts. Adv. Cyclic Nucleotide Protein Phosphorylation Res. 16:303.
38. Taira, M., S. Hockman, J. Calvo, M. Taira, and P. Belfrage. 1993. Molecular cloning of the adipocyte hormone-sensitive cyclic GMP inhibited cyclic nucleotide phosphodiesterase. J. Biol. Chem. 268:18573.
39. Parezzas, M., A. Saltiel, and D. Le Roth. 1997. Insulin-like growth factor 1 inhibits apoptosis using the phosphatidylinositol-3-kinase and mitogen-activated protein kinase pathways. J. Biol. Chem. 272:154.
40. Kaulfman-Zeh, A., P. Rodriguez-Viciana, E. Ulrich, G. Gilbert, P. Coffer, J. Downward, and G. Evan. 1997. Suppression of c-Myc-induced apoptosis by Ras signalling through PI-3-K and PKB. Nature 385:544.
41. Grande, J. P., C. S. C. Chini, J. P. Grande, E. N. Chini, and T. P. Dousa. 1996. Compartmentalization of cAMP signaling in renal mesangial cells by cAMP phosphodiesterase isoenzymes PDE4 and PDE3. Mol. Biol. Cell S7:10a.
42. Reinhart, R., E. Chen, J. Zhou, M. Taira, T. Murata, V. Manganiello, and C. Bundy. 1995. Distinctive anatomical patterns of expression for cGMP-inhibited cyclic nucleotide phosphodiesterase. J. Clin. Invest. 95:1528.
43. Cheung, P., H. Xu, M. McLaughlin, F. Ghazaleh, G. Livi, and R. Colman. 1996. Human platelet cGI-PDE: expression in yeast and localization of the catalytic domain by deletion mutagenesis. Blood 88:1321.
44. Hurwitz, R., K. Hirsch, D. Clark, V. Holcombe, and M. Hurwitz. 1990. Induction of a calcium/calmodulin-dependent phosphodiesterase during phytohaemagglutinin-stimulated lymphocyte mitogenesis. J. Biol. Chem. 265:8901.
45. Tomlinson, P., J. Wilson, and A. Stewart. 1995. Salbutamol inhibits the proliferation of human airway smooth muscle cells grown in culture: relationship to elevated cAMP levels. Biochem. Pharmacol. 49:1809.
46. Graves, L., K. Bornfeldt, E. Raines, B. Potts, S. MacDonald, R. Ross, and E. Krebs. 1993. Protein kinase A antagonizes platelet-derived growth factor-induced signalling by mitogen-activated protein kinase in human arterial smooth muscle cells. Proc. Natl. Acad. Sci. USA 90:10300.
47. Wu, J., R. Dent, T. Jelinek, A. Wolfman, M. Weber, and T. Sturgill. 1993. Inhibition of the EGF-activated MAP kinase signalling pathway by adenosine 3-5-monophosphate. Science 262:1065.
48. Cook, S., and F. McCormick. 1993. Inhibition by cAMP of Ras-dependent activation of Raf. Science 262:1069.
49. Hsueh, Y., and M. Lai. 1995. c-Jun N-terminal kinase but not mitogen-activated protein kinase is sensitive to cAMP inhibition in T-lymphocytes. J. Biol. Chem. 270:18094.
50. Tamir, A., Y. Granot, and N. Isakov. 1996. Inhibition of T lymphocyte activation by cAMP is associated with down-regulation of two parallel mitogen-activated protein kinase pathways, the extracellular signal-related kinase and c-jun N-terminal kinase. J. Immunol. 157:1514.
51. Essayan, D., S.-K. Huang, A. Kagey-Sobotka, and L. Lichtenstein. 1995. Effects of non-selective and isoenzyme-selective cyclic nucleotide phosphodiesterase inhibitors on antigen-induced cylokine gene expression in peripheral blood mononuclear cells. Am. J. Respir. Cell Mol. Biol. 13:692.
52. Chini, C. C., E. N. Chini, J. M. Williams, K. Matsousovic, and T. P. Dousa. 1994. Formation of reactive oxygen metabolites in glomeruli is suppressed by inhibition of cAMP phosphodiesterase isoenzyme type IV. Kidney Int. 46:28.
53. Manganiello, V., and M. Elks. 1986. Regulation of particulate cAMP phosphodiesterase in 3T3-L1 adipocytes. In Mechanisms of Insulin Action. P. Belfrage, J. Donner, and P. Stralfors, eds. Elsevier/North Holland Press, Amsterdam, p. 123.
54. Degerman, E., P. Belfrage, and V. C. Manganiello. 1996. Structure, localization and regulation of cGMP-inhibited phosphodiesterase (PDE3). J. Biol. Chem. 272: 6823.
55. 2+ channels by β-adrenergic agonists. Proc. Natl. Acad. Sci. USA 93:295.
56. Maurice, D., and R. Haslam. 1990. Nitroprusside enhances isoprenaline-induced increases in cAMP in rat aortic smooth muscle. Eur. J. Pharmacol. 191:471.
57. Schudt, C., S. Winder, B. Muller, and D. Ukena. 1991. Zardaverine as a selective inhibitor of phosphodiesterase isoenzymes. Biochem. Pharmacol. 42:153.
58. Torphy, T., and B. Undem. 1991. Phosphodiesterase inhibitors: new opportunities for the treatment of asthma. Thorax 46:512.
59. Giembycz, M. 1992. Could isoenzyme-selective phosphodiesterase inhibitors render bronchidilator therapy redundant in the treatment of bronchial asthma? Biochem. Pharmacol. 43:2041.
60. i. Naunyn Schmiedebergs Arch. Pharmacol. 344:682.
61. Peachell, P., B. Undem, R. Schleimer, D. MacGlashan, L. Liechtenstein, L. Cieslinski, and T. Torphy. 1992. Preliminary identification and role of phosphodiesterase isozymes in human basophils. J. Immunol. 148:2503.
62. Souness, J., C. Carter, B. Diocee, G. Hassall, L. Wood, and N. Turner. 1991. Characterization of a guinea-pig eosinophil phosphodiesterase activity. Biochem. Pharmacol. 42:937.
63. Dent, G., M. Giembycz, K. Rabe, and P. Barnes. 1991. Inhibition of eosinophil cyclic nucleolide phosphodiesterase activity and opsonized zymosan-stimulated respiratory burst by "type IV"-selective PDE inhibitors. Br. J. Pharmacol. 103: 1339.
64. Angel, J., B. Sagel, S. Walsh, T. Greten, C. Dinarello, P. Skolnik, and S. Endres. 1995. Rolipram, a specific type IV phosphodiesterase inhibitor, is a potent inhibitor of HIV-1 replication. AIDS 9:1137.